126. Incentivizing Vaccine Innovation
Friday, October 28, 2016: 10:30 AM-12:00 PM
Room: 278-282

Learning Objectives:

At the conclusion of this session, participants will be able to:

  • identify the drivers and challenges to vaccine development and innovation in 2016 
  • explain the value of developing new collaborative models to enable the development of vaccines against important pathogens for which traditional development models are failing
  • discuss the support for ID vaccine work that NIAID/NIH provides including support for a broad spectrum of vaccine development from basic research and early advanced development through post marketing clinical trials

Target Audience: Academicians, Epidemiologists, Fellows, Infection preventionists, Infectious diseases pediatricians, Infectious diseases physicians, Investigators, Lab personnel, Microbiologists, Public health practitioners, Researchers, Scientists, Vaccinologists

Tracks: Global ID, Pediatric ID, Adult ID, Investigative ID

Moderators:  Andrew Pavia, MD, FIDSA, FSHEA, FPIDS, University of Utah School of Medicine and Walter A. Orenstein, MD, FIDSA, FPIDS, Emory University

10:30 AM
Industry and NGO Perspective
Mark Feinberg, MD, PhD, FIDSA
10:55 AM
11:00 AM
NIH Perspective
Robert Johnson, PhD

11:25 AM
11:30 AM
Perspectives from the National Vaccine Program
Bruce Gellin, MD, MPH, FIDSA

11:55 AM

CME Credits: Maximum of 1.5 hours of AMA PRA Category 1 Credit™

ACPE Credits: ACPE 1.5 knowledge-based contact hours 0.15 of pharmacy CE

ACPE Number: 0221-9999-16-264-L01-P


A. Pavia, None

W. A. Orenstein, None

See more of: Symposium

Findings in the abstracts are embargoed until 12:01 a.m. CDT, Wednesday Oct. 26th with the exception of research findings presented at the IDWeek press conferences.